

The Pathogenesis of Ventilator-Associated Pneumonia: Its Relevance to Developing Effective Strategies for Prevention

Nasia Safdar MD MSc, Christopher J Crnich MD MSc, and Dennis G Maki MD

Introduction

Defense Mechanisms for Prevention of Respiratory Infection in the Normal Host

Noninvasive Ventilation

Routes of Development of VAP

Epidemic VAP

Endemic VAP

The Sequence of Oropharyngeal Colonization and VAP

Gastric Colonization and Aspiration

Prophylactic Antimicrobials for Prevention of VAP

Aerosolized Antimicrobials

Selective Aerodigestive Mucosal Antimicrobial Decontamination

Biofilms of the Endotracheal Tube

Sinusitis and Pneumonia

The Role of Respiratory Equipment in Causing VAP

Hospital Water

Hospital Air

Summary

Ventilator-associated pneumonia (VAP) is the most common nosocomial infection in the intensive care unit and is associated with major morbidity and attributable mortality. Strategies to prevent VAP are likely to be successful only if based upon a sound understanding of pathogenesis and epidemiology. The major route for acquiring endemic VAP is oropharyngeal colonization by the endogenous flora or by pathogens acquired exogenously from the intensive care unit environment, especially the hands or apparel of health-care workers, contaminated respiratory equipment, hospital water, or air. The stomach represents a potential site of secondary colonization and reservoir of nosocomial Gram-negative bacilli. Endotracheal-tube biofilm formation may play a contributory role in sustaining tracheal colonization and also have an important role in late-onset VAP caused by resistant organisms. Aspiration of microbe-laden oropharyngeal, gastric, or tracheal secretions around the cuffed endotracheal tube into the normally sterile lower respiratory tract results in most cases of endemic VAP. In contrast, epidemic VAP is most often caused by contamination of respiratory therapy equipment, bronchoscopes, medical aerosols, water (eg, *Legionella*) or air (eg, *Aspergillus* or the severe acute respiratory syndrome virus). Strategies to eradicate oropharyngeal and/or intestinal microbial colonization, such as with chlorhexidine oral care, prophylactic aerosolization of antimicrobials, selective aerodigestive mucosal antimicrobial decontamination, or the use of sucralfate rather than H₂ antagonists for stress ulcer prophylaxis, and measures to prevent aspiration, such as semirecumbent positioning or continuous subglottic suctioning, have all been shown to reduce the risk of VAP. Measures to prevent epidemic VAP include rigorous disinfection of respiratory equipment and bronchoscopes, and infection-control measures to prevent contamination of medical aerosols. Hospital water should be *Legionella*-free, and high-risk patients, espe-

cially those with prolonged granulocytopenia or organ transplants, should be cared for in hospital units with high-efficiency-particulate-arrestor (HEPA) filtered air. Routine surveillance of VAP, to track endemic VAPs and facilitate early detection of outbreaks, is mandatory. *Key words:* cross-infection, ventilator-associated pneumonia, mechanical ventilation, microbiology, nosocomial, bacteria, antibiotic, antibiotic-resistant. [Respir Care 2005;50(6):725–739. © 2005 Daedalus Enterprises]

Introduction

Mechanical ventilation is an essential feature of modern intensive care unit (ICU) care. Unfortunately, mechanical ventilation is associated with a substantial risk of ventilator-associated pneumonia (VAP). VAP is the most common nosocomial infection in the ICU, with an incidence ranging from 9% to 40%,^{1–3} and is associated with prolonged hospitalization,^{4–6} increased health care costs,⁷ and a 15–45% attributable mortality.^{8–10} Understanding the pathogenesis of VAP is essential to devising strategies for prevention of these infections.¹¹ Advances in our understanding of pathogenesis have led to the development of specific measures that can greatly reduce the risk of VAP.^{12–15} This review focuses on the pathogenesis and epidemiology of VAP and implications for prevention.

Defense Mechanisms for Prevention of Respiratory Infection in the Normal Host

In the normal nonsmoking host, multiple host defense mechanisms play an essential role in prevention of pneumonia (Table 1).^{16,17} The aerodigestive tract above the vocal cords is normally heavily colonized by bacteria; however, unless the person has chronic bronchitis or has had respiratory tract instrumentation, the lower respiratory tract is normally sterile. Normal adults aspirate frequently during sleep; yet the lower airways and pulmonary parenchyma of healthy, nonsmoking persons without lung disease are remarkably free of microbial colonization.^{18,19}

Nasia Safdar MD MSc, Christopher J Crnich MD MSc, and Dennis G Maki MD are affiliated with the Section of Infectious Diseases, Department of Medicine, University of Wisconsin Medical School, University of Wisconsin Center for Health Sciences, Madison, Wisconsin. Dennis G Maki MD is also affiliated with the Center for Trauma and Life Support, University of Wisconsin Center for Health Sciences, Madison, Wisconsin.

This research was supported by an unrestricted gift from the Oscar Rennebohm Foundation of Madison, Wisconsin.

Dennis G Maki MD presented a version of this article at the 35th RESPIRATORY CARE Journal Conference, Ventilator-Associated Pneumonia, held February 25–27, 2005, in Cancún, Mexico.

Correspondence: Dennis G Maki, University of Wisconsin Hospital and Clinics, 600 Highland Avenue, Madison WI 53792. E-mail: dgmaki@facstaff.wisc.edu.

The major defense mechanisms include anatomic airway barriers, cough reflexes, mucus,²⁰ and mucociliary clearance (Table 1).²¹ The ciliated mucosa of the upper respiratory tract has a major role in removing particulate matter and microbes that have gained access to the bronchial tree. Mucociliary clearance is a complex process, the integrity of which depends upon the composition of airway secretions, an effective mucociliary reflex, and an effective cough.²¹

Below the terminal bronchioles, the cellular and humoral immune systems are essential components of host defense.²² Alveolar macrophages and leukocytes remove particulate matter as well as potential pathogens, elaborate cytokines that activate the systemic cellular immune response, and act as antigen-presenting cells to the humoral arm of immunity.²³ Immunoglobulins and complement inactivate and opsonize bacteria and bacterial products within the respiratory tract, facilitating phagocytosis.

In the mechanically ventilated patient, a number of factors conspire to compromise host defenses: critical illness, comorbidities,²⁴ and malnutrition impair the immune system,²⁵ and, most importantly, endotracheal intubation thwarts the cough reflex,²⁶ compromises mucociliary clearance,²⁷ injures the tracheal epithelial surface,²⁸ and provides a direct conduit for rapid access of bacteria from above into the lower respiratory tract.^{29,30} It would probably be more accurate pathogenetically to rename VAP as “endotracheal-intubation-related pneumonia.” Invasive devices and procedures and antimicrobial therapy create a favorable milieu for antimicrobial-resistant nosocomial pathogens to colonize the aerodigestive tract.³¹

This combination of impaired host defenses and continuous exposure of the lower respiratory tract to large numbers of potential pathogens through the endotracheal tube (ETT) (Fig. 1) puts the mechanically ventilated patient at great jeopardy of developing VAP.

Noninvasive Ventilation

Avoidance of intubation and mechanical ventilation is the first defense against VAP. In a matched case-control study of 100 patients admitted to a medical ICU with respiratory failure, Girou et al found that rates of nosocomial pneumonia and all nosocomial infections were much lower in patients supported with noninvasive ventilation than those intubated and ventilated mechanically (8% vs

Table 1. Normal Host Defenses for Prevention of Pneumonia

Anatomy of airways
Cough reflex
Mucus
Mucociliary clearance
Alveolar macrophages
Leukocytes
Immunoglobulins
Complement
Lactoferrin
Basement membrane

22%, 18% vs 60%, $p = 0.04$, and $p < 0.001$, respectively). Moreover, the proportion of patients receiving antibiotics for nosocomial infection (8% vs 26%, $p = 0.01$), length of ICU stay (9 vs 15 d, $p = 0.02$), and crude mortality (4% vs 26%, $p = 0.002$) were all far lower among patients receiving noninvasive ventilation.³² Randomized trials have found similar results,^{33–35} and a recent meta-analysis showed that patients with exacerbations of chronic obstructive pulmonary disease supported by noninvasive ventilation had a 62% reduction in mortality, compared with patients who were intubated and mechanically ventilated.³⁶

Routes of Development of VAP

In order for microorganisms to cause VAP, they must first gain access to the normally sterile lower respiratory tract, where they can adhere to the mucosa and produce sustained infection. Microorganisms gain access by one of 4 mechanisms (see Fig. 1): (1) by aspiration of microbe-laden secretions, either from the oropharynx directly or, secondarily, by reflux from the stomach into the oropharynx, then into the lower respiratory tract;^{37–39} (2) by direct extension of a contiguous infection, such as a pleural-space infection;⁴⁰ (3) through inhalation of contaminated air or medical aerosols;⁴¹ or (4) by hematogenous carriage of microorganisms to the lung from remote sites of local infection, such as vascular or urinary catheter-related bloodstream infection.^{42–44}

Epidemic VAP

Outbreaks of VAP due to contamination of respiratory therapy equipment, bronchoscopes, and endoscopes have been well described (Table 2).^{41,45–148} For example, Takigawa et al reported 16 episodes of hospital-acquired pneumonia due to *Burkholderia cepacia* caused by contamination of inhaled medication nebulizer reservoirs.⁵⁰ Srinivasan et al reported 28 episodes of pneumonia caused by *Pseudomonas aeruginosa* linked epidemiologically to contaminated bronchoscopes with defective biopsy-port

caps;¹⁰² the outbreak occurred despite adherence to disinfection and sterilization guidelines.¹⁰⁸

Since the first reports of large outbreaks of severe acute respiratory syndrome (SARS) in 2003, in which more than 8,000 persons in China, Hong Kong, Singapore, Vietnam, Taiwan, and Canada ultimately became infected and 9.6% died,¹¹⁸ major advances have been made in our understanding of the epidemiology and modes of transmission of this remarkably virulent new human coronavirus.¹¹⁹ SARS spreads almost exclusively in respiratory droplets from person to person, rarely by distant airborne spread or contact. The risk of acquiring SARS is far higher in the hospital than in the community, and nearly one half of the early cases involved health care workers or hospitalized patients infected secondarily after admission.^{119,120} Although SARS has been contained for now, if it returns it will pose an ongoing threat to patients and health care workers as a cause of severe nosocomial pneumonia.

Outbreaks of other respiratory pathogens, such as *Legionella pneumophila*, influenza A, or respiratory syncytial virus, are well described in health care institutional settings (Table 2).^{121–127}

In the mid-1980s, tuberculosis rates in the United States rose after a half-century of decline, and many nosocomial outbreaks with multiple-drug-resistant strains were documented. In one such outbreak investigated by the Centers for Disease Control, 6 cases of tuberculosis occurred following exposure to a source patient who had spent several weeks in the hospital before being placed in respiratory isolation.¹²⁸ Transmission of tuberculosis through contaminated bronchoscopes and respiratory equipment has also been reported.^{53,104}

Although pseudo-outbreaks with nontuberculous mycobacteria far outnumber epidemics of true disease, nosocomial outbreaks caused by these ubiquitous environmental organisms are well described, most often in association with contaminated hospital water (Table 2).^{68,69}

Endemic VAP

For most endemic VAPs, the most important mechanism of infection is gross or micro-aspiration of oropharyngeal organisms into the distal bronchi, followed by bacterial proliferation and parenchymal invasion. Inflammation of the bronchiole wall involves the alveolar septi and air spaces, leading to bronchopneumonia.

Pathogens causing VAP may be part of the host's endogenous flora at the time of hospitalization or may be acquired exogenously after admission to the health care institution, from the hands, apparel, or equipment of health care workers, hospital environment, and use of invasive devices (see Fig. 1).

Although most epidemics of VAP have stemmed from direct infection of the lower airway by exogenous organ-




Fig. 1. Routes of colonization/infection in mechanically ventilated patients. Colonization of the aerodigestive tract may occur endogenously (A and B) or exogenously (C through F). Exogenous colonization may result in primary colonization of the oropharynx or may be the result of direct inoculation into the lower respiratory tract during manipulations of respiratory equipment (D), during using of respiratory devices (E), or from contaminated aerosols (F).

isms such as Gram-negative bacilli, *Legionella*, or *Aspergillus*, epidemics can also be insidious, with colonization of the upper airway and cases of VAP occurring only days or even weeks later.

The Sequence of Oropharyngeal Colonization and VAP

The normal flora of the oropharynx in the nonintubated patient without critical illness is composed predominantly of viridans streptococci, *Haemophilus* species, and anaerobes. Salivary flow and content (immunoglobulin, fibronectin) are the major host factors maintaining the normal flora of the mouth (and dental plaque). Aerobic Gram-negative bacilli are rarely recovered from the oral secretions of healthy patients.¹⁴⁹ During critical illness, especially in ICU patients, the oral flora shifts dramatically to a predominance of aerobic Gram-negative bacilli and *Staphylococcus aureus*.¹⁵⁰ Bacterial adherence to the orotracheal mucosa of the mechanically ventilated patient is facilitated by reduced mucosal immunoglobulin A and increased protease production, exposed and denuded mucous membranes, elevated airway pH, and increased numbers of airway receptors for bacteria, due to acute illness and antimicrobial use.

Numerous studies show that colonization of the oropharynx by aerobic Gram-negative and Gram-positive pathogens, such as *S. aureus*, is a near-universal occurrence in critically ill patients receiving mechanical venti-

lation.^{151–154} In a study of 80 ventilated patients, de la Torre et al found that in 19 patients with secondary tracheal colonization, 46% of the microorganisms isolated from the trachea had previously been isolated from the pharynx.³⁷ In a more recent study of 48 trauma patients, Ewig et al found that, upon admission to the ICU, patients were colonized mainly with *S. aureus*, *Haemophilus influenzae*, and *Streptococcus pneumoniae*; however, follow-up cultures showed rapid replacement of the normal oropharyngeal flora by enteric Gram-negative bacilli and *P. aeruginosa*. Oropharyngeal colonization was a powerful independent predictor of subsequent tracheobronchial colonization (odds ratio 23.9, 95% confidence interval 3.8–153.3).³⁸ George et al reported similar findings: 42% of the pathogens isolated from 26 patients with VAP were previously recovered from the oropharynx.³⁹

Aspiration of oropharyngeal contents containing a large bacterial inoculum overwhelms host defenses already compromised by critical illness and the presence of an ETT, thus leading to the development of VAP.

Understanding this sequence of pathophysiologic events, it would seem logical that reducing concentrations of oral microorganisms should have a beneficial effect for prevention of VAP (Table 3). Four studies have evaluated the use of scheduled oral care with a chlorhexidine antiseptic solution for prevention of VAP;^{155–158} chlorhexidine oral care reduced the incidence of oral microbial colonization and VAP. The use of chlorhexidine for oral antiseptics warrants further study and consideration for application in clin-

THE PATHOGENESIS OF VENTILATOR-ASSOCIATED PNEUMONIA

Table 2. Reported Outbreaks of Ventilator-Associated Pneumonia Traced to Environmental Sources

Source of Outbreak	Reference(s)	Organisms
Reusable electronic ventilator probes and sensors	54–56	<i>Burkholderia cepacia</i> <i>Stenotrophomonas maltophilia</i>
Nebulized medication	41, 45–53	<i>Burkholderia cepacia</i> <i>Pseudomonas aeruginosa</i> <i>Mycobacterium tuberculosis</i>
Ventilator circuits and equipment, humidifiers, and respirometers	57–66	<i>Acinetobacter calcoaceticus</i> <i>Burkholderia cereus</i> <i>Pseudomonas aeruginosa</i>
Ice and water	67–99	<i>Legionella pneumophila</i> <i>Pseudomonas aeruginosa</i> Nontuberculous mycobacteria
Bronchoscopes	100–108	<i>Pseudomonas aeruginosa</i> <i>Mycobacterium tuberculosis</i> Nontuberculous mycobacteria
Fingernails and hands of health care workers	109–112	<i>Pseudomonas aeruginosa</i> <i>Klebsiella pneumoniae</i>
Miscellaneous		
Milk bank pasteurizer	113	<i>Pseudomonas aeruginosa</i>
Blood-gas analyzer	114	<i>Pseudomonas aeruginosa</i>
Mouthwash	115	<i>Burkholderia cepacia</i>
Food coloring dye	116, 117	<i>Pseudomonas aeruginosa</i> <i>Burkholderia cepacia</i>
Infected patients or health-care workers	118–133	SARS human coronavirus Influenza A, respiratory syncytial virus <i>Mycobacterium tuberculosis</i> Methicillin-resistant <i>Staphylococcus aureus</i>
Ambient air	134–148	<i>Aspergillus</i> , zygomycetes

ical practice. The use of aerosolized antimicrobials and the topical application of antimicrobial combinations to the aerodigestive mucosa for prevention of VAP are discussed below.

Gastric Colonization and Aspiration

The stomach has been posited to be an important reservoir of organisms that cause VAP (see Fig. 1).³⁷ In healthy persons, few bacteria entering the stomach survive in the presence of gastric acid. Conditions that reduce the gastric pH, such as achlorhydria, treatment with H₂ antagonists or proton-pump inhibitors, or enteral nutrition, predispose to bacterial proliferation in the stomach.^{159–162} Studies have shown a powerful relationship between a high gastric pH and massive overgrowth of gastric bacteria.^{159–162} Gastric microorganisms can reflux up the esophagus, abetted by recumbency and the ever-present naso- or oro-gastric tube, and are aspirated into the trachea. Direct and indirect evidence exists to implicate the stomach as a potential reservoir of bacteria causing VAP.^{163–165} Numerous studies have shown that gastric contents can be aspirated into the lower airways, despite the presence of an endotracheal cuff.^{166,167} However, recent studies suggest that the stomach, although often heavily colonized by enteric Gram-

negative bacilli, is not the primary source for lower-airway colonization with nosocomial pathogens, and the gastropulmonary route is not a major pathogenetic route for development of VAP.¹⁶⁸

In a prospective, randomized, double-blind study in ICU patients, Bonten et al compared antacids and sucralfate and measured intragastric acidity. Colonization by *Enterobacteriaceae* occurred in the stomach, trachea, and oropharynx; however, intragastric acidity did not appear to influence the development of VAP.¹⁶⁹ In another analysis of the same study, the same group of investigators showed that oropharyngeal colonization by *Enterobacteriaceae* was an important independent risk factor for VAP; in contrast, gastric colonization by *Enterobacteriaceae* was not found to increase the risk of VAP.¹⁷⁰

Prophylactic Antimicrobials for Prevention of VAP

Aerosolized Antimicrobials

The delivery of antimicrobials through aerosol administration allows for the deposition of antimicrobial agents directly at the site of infection, in concentrations not achievable with systemic administration. The adjunctive use of

THE PATHOGENESIS OF VENTILATOR-ASSOCIATED PNEUMONIA

Table 3. Measures for Prevention of Ventilator-Associated Pneumonia Based on Our Understanding of Pathogenesis and Epidemiology

Source of VAP Pathogen	Prevention Goal	Specific Measures
Aerodigestive colonization	Prevent colonization by exogenous routes	Hand hygiene Microbial surveillance and targeted barrier isolation Preemptive barriers: Routine gloving Routine gowning Dedicated equipment
	Suppress oropharyngeal mucosal colonization	Oral decontamination with chlorhexidine Selective digestive tract antimicrobial decontamination Aerosolized antimicrobials Sucralfate instead of H ₂ -blockers
	Prevent aspiration	Noninvasive ventilation Semirecumbant positioning Novel endotracheal tube permitting continuous subglottic suctioning
Contaminated respiratory therapy equipment and medical aerosols	Safe equipment and medical aerosols	Procedures for reprocessing bronchoscopes and reused respiratory therapy equipment Training and education of reprocessing staff and respiratory therapists Procedures for use of aerosolized medications
	Reducing contamination of ventilator circuit	Heat-and-moisture exchanger Periodically drain condensate from circuit Sterile water for bubble-through humidifiers Aseptic procedures for suctioning of ventilated patients
Contaminated tap water (<i>Legionella</i> species, <i>Pseudomonas aeruginosa</i>)	Safe water	Sterile water for: Cleaning respiratory therapy equipment Rinsing bronchoscopes Aerosolized medications Hospital surveillance for cases of nosocomial legionellosis Microbial surveillance of hospital water for contamination by legionellae Engineering controls for contaminated water: Superheat and flush Ultraviolet light Hyperchlorination Silver-copper ionization Ozonation
Contaminated ambient air (filamentous fungi, <i>Mycobacterium tuberculosis</i> , SARS coronavirus)	Safe air	Procedures for minimizing communicable airborne infections: Disease recognition Administrative controls Engineering controls Procedures for minimizing risk to immunocompromised patients: High-efficiency particulate arrester (HEPA)-filtered rooms N95 masks for intrahospital transports Policies and procedures for management during periods of construction and renovation

VAP = ventilator-associated pneumonia
SARS = severe acute respiratory syndrome

aerosolized antimicrobial agents has become widely practiced in the treatment of patients with cystic fibrosis,¹⁷¹ and has gained much interest for treatment of VAP, especially with the rapid emergence of nosocomial microorganisms resistant to multiple systemic antimicrobials in many ICUs. Anecdotally, aerosolized colistin¹⁷² and poly-

myxin B¹⁷³ have been used to successfully treat infections caused by a variety of multi-resistant Gram-negative bacteria, such as *P. aeruginosa* or *Acinetobacter* species, resistant to most or all available antimicrobial drugs that can be administered systemically. Moreover, a prospective randomized controlled trial has shown that adjunctive use of

aerosolized tobramycin, in addition to systemic therapy, controls respiratory-tract infections caused by Gram-negative bacilli more rapidly than systemic therapy alone, although survival did not differ between the 2 groups.¹⁷⁴

Given the early successes of aerosolized antimicrobials in the treatment of VAP, interest has also grown in using aerosolized antimicrobials for prevention, given the fundamental role of airway colonization in the pathogenesis of VAP (see Table 3). A large prospective trial more than 30 years ago showed that aerosolized polymyxin B significantly reduced airway colonization (1.6% vs 9.7%, $p < 0.01$) and VAP caused by *P. aeruginosa* (0.8% vs 4.6%, $p < 0.01$), although overall mortality from VAP was unchanged.¹⁷⁵ The authors of this study rightly pointed out the concerns of promoting antimicrobial resistance through the use of prophylactic antimicrobial agents, and we believe that further studies are needed before aerosolized antimicrobial agents can be endorsed for prevention of VAP. Notably, the heavy prophylactic use of aerosolized colistin in patients with cystic fibrosis in one center recently resulted in the very unusual emergence of a strain of *P. aeruginosa* resistant to colistin, which spread to other patients in the unit.¹⁷⁶

Selective Aerodigestive Mucosal Antimicrobial Decontamination

The use of topically-applied nonabsorbable oral antibiotics to eradicate or at least reduce aerodigestive mucosal colonization by pathogenic microorganisms (see Table 3), a process widely termed selective digestive decontamination, has been extensively studied.^{177,178} A short course of parenteral antimicrobials with a prolonged duration of topical antimicrobials has been used in most studies evaluating the efficacy of selective digestive decontamination for the prevention of VAP. More than 40 randomized controlled trials^{179,180} and 8 meta-analyses^{181–185} have undertaken to determine the efficacy of selective digestive decontamination for reducing the incidence of VAP; most, but not all, have found a beneficial effect in VAP but an inconsistent effect on ICU mortality. Regardless of efficacy, a very real concern relates to the potential for promoting antimicrobial resistance with long-term use of selective digestive decontamination.^{186,187} Recent studies have justified this concern and further dampened enthusiasm for this approach in U.S. centers.

Most of the studies were not designed to assess the relative effect of the 2 major components of selective digestive decontamination (topical and systemic agents) on the prevention of VAP. Future studies especially need to more clearly evaluate antimicrobial resistance as a major end point, incorporating the use of selective media for surveillance cultures to enhance recovery of antibiotic-resistant nosocomial pathogens.

Randomized controlled trials have shown that simple strategies to prevent aspiration, such as semirecumbent (rather than supine) positioning,¹⁸⁸ and continuous suctioning of subglottic secretions,^{189–192} can greatly reduce the incidence of VAP (see Table 3), and are far more attractive ecologically than the heavy use of prophylactic antimicrobials.

Biofilms of the Endotracheal Tube

The ETT has also been posited as a reservoir for infecting microorganisms, which adhere to the surface of the foreign body,¹⁹³ producing a biofilm. Biofilms are highly resistant to the effects of antibiotics and host defenses and may represent a site of cumulative and persistent colonization by antibiotic-resistant nosocomial pathogens.¹⁹⁴ In a prospective study of 40 patients with VAP, Adair et al found that 70% of patients with VAP had identical pathogens isolated from both endotracheal biofilm and tracheal secretions.¹⁹⁴ In another prospective study, Feldman et al obtained cultures from oropharyngeal, gastric, respiratory tract, and ETT twice daily for 5 days, and noted the following sequence of colonization in patients undergoing mechanical ventilation: the oropharynx (36 h), the stomach (36–60 h), the lower respiratory tract (60–84 h), and, thereafter, the ETT (60–96 h). Nosocomial pneumonia occurred in 13 patients, and in 8 cases identical organisms were recovered from lower-respiratory-tract specimens and from material lining the interior of the ETT.¹⁹⁵

This discovery has led to the development of novel antiseptic-impregnated ETTs. In a laboratory model, the effect of ETTs impregnated with chlorhexidine and silver carbonate was tested *in vitro* against *S. aureus*, methicillin-resistant *S. aureus*, *P. aeruginosa*, *Acinetobacter baumannii*, and *Enterobacter aerogenes*. After 5 days of incubation, bacterial colony counts on all ETT segments, both antiseptic-impregnated and control ETTs were measured. There was a significant reduction in colony counts of organisms recovered from the antiseptic-impregnated ETTs (1–100 colony-forming units per tube, compared with 10^6 colony-forming units per tube from control ETTs).¹⁹⁶ An *in vivo* study in 12 dogs, comparing a silver-coated ETT to a standard ETT, found significantly reduced lower-respiratory-tract colonization with the silver-coated tube.¹⁹⁷ A multicenter trial to ascertain the efficacy of the chlorhexidine-silver carbonate-impregnated tube is currently underway.

Sinusitis and Pneumonia

In a prospective study of sinusitis, Holzapfel et al found that bacterial paranasal sinusitis was associated with an almost 3-fold increased risk for pneumonia (risk ratio 2.29, 95% confidence interval 1.10–4.74).¹⁹⁸ Other investiga-

tors have found similar results.^{199,200} However, it is unclear whether sinus infection precedes and then predisposes to the development of VAP or is a noncausal epiphenomenon. Further studies are needed before a systematic search for sinusitis can be recommended in every patient with VAP.

Microbiologic analysis of a sinus aspirate in a patient with suspected sinusitis and VAP may serve to assist in the diagnosis of VAP, as the pathogens causing VAP and nosocomial sinusitis are virtually identical. In a prospective study, Souweine et al found that in patients with VAP and sinusitis the same pathogens were recovered in cultures from both sites of infection.²⁰⁰

The Role of Respiratory Equipment in Causing VAP

Condensates of ventilator circuits can also be a potential source of microorganisms; numerous studies have shown that manipulation of circuits can increase the risk of VAP.^{201,202} Goularte et al found that changing circuits every 48 hours instead of every 24 hours decreased the incidence of VAP.²⁰² In a randomized trial, Kollef et al found that eliminating routine changes of ventilator circuits altogether did not result in an increased incidence of VAP and resulted in substantial cost savings.²⁰¹ Closed tracheal suctioning has been associated with an increased risk of colonization; however, the risk of VAP was not increased.²⁰³ Table 2 shows major outbreaks of VAP related to contaminated respiratory equipment or transfer of microorganisms from health-care workers or other patients to susceptible patients; most outbreaks were caused by *P. aeruginosa* and *B. cepacia*.

Hospital Water

A variety of organisms, including bacteria, mycobacteria, fungi, and parasites, are isolated from hospital water systems and have been implicated in endemic and epidemic nosocomial infections.⁷⁰ Many of these outbreaks were caused by bacteria typically thought of as "water" organisms such as *P. aeruginosa*,⁷²⁻⁷⁴ *Stenotrophomonas maltophilia*,⁷⁵ and *A. baumannii*;⁷⁶⁻⁷⁹ however, the hospital water organisms most commonly implicated in epidemic nosocomial pneumonia are the *Legionella* species (see Table 2).⁸⁰

The first reports describing *Legionella* species as human pathogens were published in 1976. The genus *Legionella* is composed of 48 different species and 70 different serotypes, although *L. pneumophila* accounts for the vast majority of human infections (> 90%), with other species, such as *Legionella longbeachae*, *Legionella bozmannii*, and *Legionella micdadei*, being isolated far less commonly.⁸¹ Nosocomial legionellosis was first described in 1979,⁸² and it is estimated that 25–45% of all cases of legionel-

losis are acquired in the health-care setting,⁸² with a mortality that approaches 30%.⁸³ *Legionella* contamination of hospital potable water remains underappreciated, despite studies showing that *Legionella* species can be recovered from 12–70% of hospital water systems,⁸⁴ and studies have demonstrated an uncovering of unrecognized cases when aggressive diagnostic and surveillance methods are employed.^{86,87} Characteristics of water systems that enhance legionella contamination of hospital water include plumbing with dead-ends that produce water stagnation, large-volume water heaters that result in inefficient heating of hospital water, water sediment build-up, heated-water temperatures $\leq 60^{\circ}\text{C}$, tap-water temperatures $\leq 50^{\circ}\text{C}$, water pH ≤ 8 , and municipal water not treated with monochloramine.⁸⁸⁻⁸⁹

Hospital Air

Filamentous fungi and molds are the primary microorganisms routinely found in ambient air, including hospital air, and more than 2 decades ago infections caused by these organisms were considered a curiosity. The enormous increase in immunocompromised patients as a result of greatly increased bone-marrow and solid-organ transplantation and the epidemic of acquired immune deficiency syndrome has changed this view,¹³⁴ and numerous outbreaks of filamentous fungal infection have now been reported (see Table 2), most linked to new construction or renovation or to breakdowns in air-handling systems.¹³⁵ Pegues et al reported an unusual outbreak of invasive pulmonary aspergillosis among orthotopic liver-transplant recipients, traced to massive aerosolization of spores following wound dressing changes in a patient with a surgical wound infection caused by *Aspergillus fumigatus*.¹³⁵

Routine high-efficiency-particulate-arrestor (HEPA) filtration of intake air in units with patients at risk can greatly reduce the risk of invasive fungal infection (see Table 3),^{136,137} although outbreaks of infections caused by filamentous fungi have continued to be reported during periods of construction, when ambient levels of fungi rise sharply and overwhelm engineering controls.^{138,148}

The spread of the SARS virus was effectively contained by stringent respiratory isolation precautions designed to prevent airborne transmission. Routine use of high-quality filtration masks, ideally N-95 masks, but even surgical masks,¹³⁰ combined with full barrier precautions in a single room was highly effective in preventing spread to other patients and health care workers where it was most carefully studied, in Hong Kong, Singapore, and Canada.¹³¹ Persons exposed to SARS must be quarantined; however, there is no need to extend the period of quarantine of exposed persons beyond 10 days, as very few persons develop clinical SARS more than 10 days after exposure.¹³²

The prevention of nosocomial transmission of community-acquired respiratory viral infections, such as influenza, also deserves mention, given the numerous institutional outbreaks reported (see Table 2).¹³³ Infection control practices to prevent nosocomial spread of respiratory viral infections include: (1) a high level of immunization of patients and staff against influenza; (2) prevention of patient contact with persons (friends, family, and health-care staff) who have active respiratory symptoms; (3) use of rapid diagnostic tests to quickly identify symptomatic patients with potentially transmissible viral pathogens, to facilitate early implementation of isolation precautions; (4) cohorting patients with confirmed infection when single rooms are not available; and (5) placement of patients with suspected community-acquired respiratory viral infections in droplet isolation precautions. The use of more aggressive isolation procedures, such as contact and airborne isolation precautions, with or without the use of prophylactic antiviral agents, deserves consideration with outbreaks among very-high-risk patients.¹⁵

Summary

In sum, the major route of pulmonary infection in *endemic* VAP is aspiration of oropharyngeal secretions colonized by nosocomial organisms, especially enteric Gram-negative bacilli or *S. aureus*. The stomach and/or the intestine may play a secondary role as a reservoir of nosocomial organisms; however, the digestive tract does not appear to be the *initial* site of colonization in most cases of VAP. ETT biofilm may contribute to sustaining colonization, creating an increased risk of infection, and further studies are needed to determine the exact role that ETT biofilm plays in facilitating infection and sustaining it. With *epidemic* VAP, contaminated respiratory equipment and medical aerosols are the major sources; however, contaminated hospital air (*Aspergillus*) and water (*Legionella*) are also important causes of nosocomial pneumonia deriving from environmental reservoirs. Future research needs to focus on delineating more clearly the sequence of aerodigestive-tract colonization, including the relative importance of the various sites of potential early colonization: the oropharynx, stomach, and trachea. Better understanding of pathogenesis and epidemiology is essential to devising more effective strategies for prevention of VAP.

REFERENCES

1. Ibrahim EH, Mehringer L, Prentice D, Sherman G, Schaiff R, Fraser V, Kollef MH. Early versus late enteral feeding of mechanically ventilated patients: results of a clinical trial. *JPEN J Parenter Enteral Nutr* 2002;26(3):174–181.
2. Kollef MH, Vlasnik J, Sharpless L, Pasque C, Murphy D, Fraser V. Scheduled change of antibiotic classes: a strategy to decrease the

- incidence of ventilator-associated pneumonia. *Am J Respir Crit Care Med* 1997;156(4 Pt 1):1040–1048.
3. Sirvent JM, Torres A, El-Ebiary M, Castro P, de Batlle J, Bonet A. Protective effect of intravenously administered cefuroxime against nosocomial pneumonia in patients with structural coma. *Am J Respir Crit Care Med* 1997;155(5):1729–1734.
4. Rello J, Ollendorf DA, Oster G, Vera-Llonch M, Bellm L, Redman R, et al. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. *Chest* 2002;122(6):2115–2121.
5. Bercault N, Boulain T. Mortality rate attributable to ventilator-associated nosocomial pneumonia in an adult intensive care unit: a prospective case-control study. *Crit Care Med* 2001;29(12):2303–2309.
6. Heyland DK, Cook DJ, Griffith L, Keenan SP, Brun-Buisson C. The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. *The Canadian Critical Trials Group. Am J Respir Crit Care Med* 1999;159(4 Pt 1):1249–1256.
7. Warren DK, Shukla SJ, Olsen MA, Kollef MH, Hollenbeak CS, Cox MJ, et al. Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center. *Crit Care Med* 2003;31(5):1312–1317.
8. Craig CP, Connelly S. Effect of intensive care unit nosocomial pneumonia on duration of stay and mortality. *Am J Infect Control* 1984;12(4):233–238.
9. Fagon JY, Chastre J, Hance AJ, Montravers P, Novara A, Gibert C. Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. *Am J Med* 1993;94(3):281–288.
10. Cunnion KM, Weber DJ, Broadhead WE, Hanson LC, Pieper CF, Rutala WA. Risk factors for nosocomial pneumonia: comparing adult critical-care populations. *Am J Respir Crit Care Med* 1996;153(1):158–162.
11. Maki DG. Control of colonization and transmission of pathogenic bacteria in the hospital. *Ann Intern Med* 1978;89(5 Pt 2 Suppl):777–780.
12. Cassiere HA, Niederman MS. New etiopathogenic concepts of ventilator-associated pneumonia. *Semin Respir Infect* 1996;11:13–23.
13. Collard HR, Saint S, Matthay MA. Prevention of ventilator-associated pneumonia: an evidence-based systematic review. *Ann Intern Med* 2003;138(6):494–501.
14. Kollef MH. Prevention of hospital-associated pneumonia and ventilator-associated pneumonia. *Crit Care Med* 2004;32(6):1396–1405.
15. Tablan OC, Anderson LJ, Besser R, Bridges C, Hajjeh R. Guidelines for preventing health-care-associated pneumonia. 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. *MMWR Recomm Rep* 2004;53(RR-3):1–36.
16. Zhang P, Summer WR, Bagby GJ, Nelson S. Innate immunity and pulmonary host defense. *Immunol Rev* 2000;173:39–51.
17. Mason CM, Nelson S. Normal host defenses and impairments associated with the delayed resolution of pneumonia. *Semin Respir Infect* 1992;7(4):243–255.
18. Lees AW, McNaught W. Bacteriology of lower-respiratory-tract secretions, sputum, and upper-respiratory-tract secretions in “normals” and chronic bronchitics. *Lancet* 1959;2:1112–1115.
19. Laurenzi GA, Potter RT, Kass EH. Bacteriologic flora of the lower respiratory tract. *N Engl J Med* 1961;265:1273–1278.
20. Lillehoj ER, Kim KC. Airway mucus: its components and function. *Arch Pharm Res* 2002;25(6):770–780.
21. Salathe M, Wanner A. Nospecific host defenses: mucociliary clearance and cough. In: Niederman M, ed. *Respiratory Infections*. Philadelphia: Saunders; 1994:17–32.
22. Zeiher BG, Hornick DB. Pathogenesis of respiratory infections and host defenses. *Curr Opin Pulm Med* 1996;2(3):166–173.

23. Strieter RM, Belperio JA, Keane MP. Host innate defenses in the lung: the role of cytokines. *Curr Opin Infect Dis* 2003;16(3):193–198.
24. Johanson WG, Pierce AK, Sanford JP. Changing pharyngeal bacterial flora in hospitalized patients: emergence of Gram-negative bacilli. *N Engl J Med* 1969;281(21):1137–1140.
25. Sigalet DL, Mackenzie SL, Hameed SM. Enteral nutrition and mucosal immunity: implications for feeding strategies in surgery and trauma. *Can J Surg* 2004;47(2):109–116.
26. Gal TJ. How does tracheal intubation alter respiratory mechanics? *Probl Anesth* 1988;2:191–200.
27. Klainer AS, Turndorf H, Wu WH, Maewal H, Allender P. Surface alterations due to endotracheal intubation. *Am J Med* 1975;58(5):674–683.
28. Cooper JD, Grillo HC. Experimental production and prevention of injury due to cuffed tracheal tubes. *Surg Gynecol Obstet* 1969;129(6):1235–1241.
29. Levine SA, Niederman MS. The impact of tracheal intubation on host defenses and risks for nosocomial pneumonia. *Clin Chest Med* 1991;12(3):523–543.
30. Bone DK, Davis JL, Zuidema GD, Cameron JL. Aspiration pneumonia. Prevention of aspiration in patients with tracheostomies. *Ann Thoracic Surg* 1974;18(1):30–37.
31. Safdar N, Maki DG. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant *Staphylococcus aureus*, enterococcus, Gram-negative bacilli, *Clostridium difficile* and *Candida*. *Ann Intern Med* 2002;136(11):834–844.
32. Girou E, Schortgen F, Delclaux C, Brun-Buisson C, Blot F, Lefort Y, et al. Association of noninvasive ventilation with nosocomial infections and survival in critically ill patients. *JAMA* 2000;284(18):2361–2367.
33. Bersten AD, Holt AW, Vedig AE, Skowronski GA, Baggoley CJ. Treatment of severe cardiogenic pulmonary edema with continuous positive airway pressure delivered by face mask. *N Engl J Med* 1991;325(26):1825–1830.
34. Bott J, Carroll MP, Conway JH, Keilty SE, Ward EM, Brown AM, et al. Randomised controlled trial of nasal ventilation in acute ventilatory failure due to chronic obstructive airways disease. *Lancet* 1993;341(8860):1555–1557.
35. Brochard L, Mancebo J, Wysocki M, Lofaso F, Conti G, Rauss A, et al. Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. *N Engl J Med* 1995;333(13):817–821.
36. Lightowler JV, Wedzicha JA, Elliott MW, Ram FS. Non-invasive positive pressure ventilation to treat respiratory failure resulting from exacerbations of chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis. *BMJ* 2003;326(7382):185.
37. de la Torre FJ, Pont T, Ferrer A, Rossello J, Palomar M, Planas M. Pattern of tracheal colonization during mechanical ventilation. *Am J Respir Crit Care Med* 1995;152(3):1028–1033.
38. Ewig S, Torres A, El-Ebiary M, Fabregas N, Hernandez C, Gonzalez J, et al. Bacterial colonization patterns in mechanically ventilated patients with traumatic and medical head injury. Incidence, risk factors, and association with ventilator-associated pneumonia. *Am J Respir Crit Care Med* 1999;159(1):188–198.
39. George DL, Falk PS, Wunderink RG, Leeper KV Jr, Meduri GU, Steere EL, et al. Epidemiology of ventilator-acquired pneumonia based on protected bronchoscopic sampling. *Am J Respir Crit Care Med* 1998;158(6):1839–1847.
40. Estes RJ, Meduri GU. The pathogenesis of ventilator-associated pneumonia: I. Mechanisms of bacterial transcolonization and airway inoculation. *Intensive Care Med* 1995;21(4):365–383.
41. Hamill RJ, Houston ED, Georghiou PR, Wright CE, Koza MA, Cadle RM, et al. An outbreak of *Burkholderia* (formerly *Pseudomonas cepacia*) respiratory tract colonization and infection associated with nebulized albuterol therapy. *Ann Intern Med* 1995;122(10):762–766.
42. Alcon A, Fabregas N, Torres A. Hospital-acquired pneumonia: etiologic considerations. *Infect Dis Clin North Am* 2003;17(4):679–695.
43. Maki DG. Preventing infection in intravenous therapy. *Anesth Analg* 1977;56(1):141–153.
44. Crnich CJ, Maki DG. The promise of novel technology for the prevention of intravascular device-related bloodstream infection. II. Long-term devices. *Clin Infect Dis* 2002;34(10):1362–1368.
45. Edmondson EB, Reinartz JA, Pierce AK, Sanford JP. Nebulization equipment. A potential source of infection in Gram-negative pneumonias. *Am J Dis Child* 1966;111(4):357–360.
46. Mertz JJ, Scharer L, McClement JH. A hospital outbreak of Klebsiella pneumonia from inhalation therapy with contaminated aerosol solutions. *Am Rev Respir Dis* 1967;95(3):454–460.
47. Ringrose RE, McKown B, Felton FG, Barclay BO, Muchmore HG, Rhoades ER. A hospital outbreak of *Serratia marcescens* associated with ultrasonic nebulizers. *Ann Intern Med* 1968;69(4):719–729.
48. Gorman GW, Yu VL, Brown A, Hall JA, Martin WT, Bibb WF, et al. Isolation of Pittsburgh pneumonia agent from nebulizers used in respiratory therapy. *Ann Intern Med* 1980;93(4):572–573.
49. Craven DE, Lichtenberg DA, Goularte TA, Make BJ, McCabe WR. Contaminated medication nebulizers in mechanical ventilator circuits. Source of bacterial aerosols. *Am J Med* 1984;77(5):834–838.
50. Takigawa K, Fujita J, Negayama K, Yamagishi Y, Yamaji Y, Ouchi K, et al. Nosocomial outbreak of *Pseudomonas cepacia* respiratory infection in immunocompromised patients associated with contaminated nebulizer devices. *Kansenshogaku Zasshi* 1993;67(11):1115–1125.
51. Cobben NA, Drent M, Jonkers M, Wouters EF, Vanechoutte M, Stobberingh EE. Outbreak of severe *Pseudomonas aeruginosa* respiratory infections due to contaminated nebulizers. *J Hosp Infect* 1996;33:63–70.
52. Reboli AC, Koshinski R, Arias K, Marks-Austin K, Stieritz D, Stull TL. An outbreak of *Burkholderia cepacia* lower respiratory tract infection associated with contaminated albuterol nebulization solution. *Infect Control Hosp Epidemiol* 1996;17:741–743.
53. Southwick KL, Hoffmann K, Ferree K, Matthews J, Salfinger M. Cluster of tuberculosis cases in North Carolina: possible association with atomizer use. *Am J Infect Control* 2001;29(1):1–6.
54. Weems JJ, Jr. Nosocomial outbreak of *Pseudomonas cepacia* associated with contamination of reusable electronic ventilator temperature probes. *Infect Control Hosp Epidemiol* 1993;14:583–586.
55. Berthelot P, Grattard F, Mahul P, et al. Ventilator temperature sensors: an unusual source of *Pseudomonas cepacia* in nosocomial infection. *J Hosp Infect* 1993;25:33–43.
56. Rogues AM, Maugein J, Allery A, et al. Electronic ventilator temperature sensors as a potential source of respiratory tract colonization with *Stenotrophomonas maltophilia*. *J Hosp Infect* 2001;49:289–292.
57. Griebble HG, Colton FR, Bird TJ, Toigo A, Griffith LG. Fine-particle humidifiers. Source of *Pseudomonas aeruginosa* infections in a respiratory-disease unit. *N Engl J Med* 1970;282(10):531–535.
58. Cross AS, Roup B. Role of respiratory assistance devices in endemic nosocomial pneumonia. *Am J Med* 1981;70(3):681–685.
59. Hovig B. Lower respiratory tract infections associated with respiratory therapy and anaesthesia equipment. *J Hosp Infect* 1981;2(4):301–315.
60. Pegues CF, Pegues DA, Ford DS, et al. *Burkholderia cepacia* respiratory tract acquisition: epidemiology and molecular character-

- ization of a large nosocomial outbreak. *Epidemiol Infect* 1996;116:309–317.
61. Hartstein AI, Rashad AL, Liebler JM, et al. Multiple intensive care unit outbreak of *Acinetobacter calcoaceticus* subspecies anitratus respiratory infection and colonization associated with contaminated, reusable ventilator circuits and resuscitation bags. *Am J Med* 1988; 85:624–631.
 62. Gray J, George RH, Durbin GM, Ewer AK, Hocking MD, Morgan ME. An outbreak of *Bacillus cereus* respiratory tract infections on a neonatal unit due to contaminated ventilator circuits. *J Hosp Infect* 1999;41:19–22.
 63. Jumaa P, Chattopadhyay B. Outbreak of gentamicin, ciprofloxacin-resistant *Pseudomonas aeruginosa* in an intensive care unit, traced to contaminated quivers. *J Hosp Infect* 1994;28:209–218.
 64. Kolmos HJ, Thuesen B, Nielsen SV, Lohmann M, Kristoffersen K, Rosdahl VT. Outbreak of infection in a burns unit due to *Pseudomonas aeruginosa* originating from contaminated tubing used for irrigation of patients. *J Hosp Infect* 1993;24:11–21.
 65. Cunha BA, Klimek JJ, Gracewski J, McLaughlin JC, Quintiliani R. A common source outbreak of acinetobacter pulmonary infections traced to Wright respirometers. *Postgrad Med J* 1980;56:169–172.
 66. Cefai C, Richards J, Gould FK, McPeake P. An outbreak of acinetobacter respiratory tract infection resulting from incomplete disinfection of ventilatory equipment. *J Hosp Infect* 1990;15:177–182.
 67. Burns DN, Wallace RJ Jr, Schultz ME, Zhang YS, Zubairi SQ, Pang YJ, et al. Nosocomial outbreak of respiratory tract colonization with *Mycobacterium fortuitum*: demonstration of the usefulness of pulsed field gel electrophoresis in epidemiological investigation. *Am Rev Respir Dis* 1991;144(5):1153–1159.
 68. Laussucq S, Baltch AL, Smith RP, Smithwick RW, Davis BJ, Desjardins EK, et al. Nosocomial *Mycobacterium fortuitum* colonization from a contaminated ice machine. *Am Rev Respir Dis* 1988;138(4): 891–894.
 69. Wallace RJ, Brown BA, Griffith DE. Nosocomial outbreaks/pseudo-outbreaks caused by nontuberculous mycobacteria. *Ann Rev Microbiol* 1998;52:453–490.
 70. Anaissie EJ, Penzak SR, Dignani MC. The hospital water supply as a source of nosocomial infections: a plea for action. *Arch Internal Med* 2002;162:1483–1492.
 71. Rudnick JR, Beck-Sague CM, Anderson RL, Schable B, Miller JM, Jarvis WR. Gram-negative bacteremia in open-heart-surgery patients traced to probable tap-water contamination of pressure-monitoring equipment. *Infect Control Hosp Epidemiol* 1996;17:281–285.
 72. Bert F, Maubec E, Bruneau B, Berry P, Lambert-Zechovsky N. Multi-resistant *Pseudomonas aeruginosa* outbreak associated with contaminated tap water in a neurosurgery intensive care unit. *J Hosp Infect* 1998;39:53–62.
 73. Trautmann M, Michalsky T, Wiedeck H, Radosavljevic V, Ruhnke M. Tap water colonization with *Pseudomonas aeruginosa* in a surgical intensive care unit (ICU) and relation to pseudomonas infections of ICU patients. *Infect Control Hosp Epidemiol* 2001;22:49–52.
 74. Reuter S, Sigge A, Wiedeck H, Trautmann M. Analysis of transmission pathways of *Pseudomonas aeruginosa* between patients and tap water outlets. *Crit Care Med* 2002;30:2222–2228.
 75. Weber DJ, Rutala WA, Blanchet CN, Jordan M, Gergen MF. Faucet aerators: A source of patient colonization with *Stenotrophomonas maltophilia*. *Am J Infect Control* 1999;27:59–63.
 76. Struelens MJ, Carlier E, Maes N, Serruys E, Quint WG, van Belkum A. Nosocomial colonization and infection with multiresistant *Acinetobacter baumannii*: outbreak delineation using DNA macrorestriction analysis and PCR-fingerprinting. *J Hosp Infect* 1993;25: 15–32.
 77. Aygun G, Demirkiran O, Utku T, et al. Environmental contamination during a carbapenem-resistant *Acinetobacter baumannii* outbreak in an intensive care unit. *J Hosp Infect* 2002;52:259–262.
 78. Simor AE, Lee M, Vearncombe M, et al. An outbreak due to multiresistant *Acinetobacter baumannii* in a burn unit: risk factors for acquisition and management. *Infect Control Hosp Epidemiol* 2002;23:261–267.
 79. Wang SH, Sheng WH, Chang YY, et al. Healthcare-associated outbreak due to pan-drug resistant *Acinetobacter baumannii* in a surgical intensive care unit. *J Hosp Infect* 2003;53:97–102.
 80. Sabria M, Yu VL. Hospital-acquired legionellosis: solutions for a preventable infection. *Lancet* 2002;2:368–373.
 81. Yu VL, Plouffe JF, Pastoris MC, et al. Distribution of *Legionella* species and serogroups isolated by culture in patients with sporadic community-acquired legionellosis: an international collaborative survey. *J Infect Dis* 2002;186:127–128.
 82. Haley CE, Cohen ML, Halter J, Meyer RD. Nosocomial Legionnaires' disease: a continuing common-source epidemic at Wadsworth Medical Center. *Ann Intern Med* 1979;90:583–586.
 83. Anonymous. Guidelines for prevention of nosocomial pneumonia. Centers for Disease Control and Prevention. *MMWR Recommend Rep* 1997;46:1–79.
 84. Benin AL, Benson RF, Besser RE. Trends in Legionnaires' disease, 1980–1998: declining mortality and new patterns of diagnosis. *Clin Infect Dis* 2002;35:1039–1046.
 85. Yu VL. Resolving the controversy on environmental cultures for Legionella: a modest proposal. *Infect Control Hosp Epidemiol* 1998; 19:893–897.
 86. Lepine LA, Jernigan DB, Butler JC, et al. A recurrent outbreak of nosocomial Legionnaires' disease detected by urinary antigen testing: evidence for long-term colonization of a hospital plumbing system. *Infect Control Hosp Epidemiol* 1998;19:905–910.
 87. Alary M, Joly JR. Factors contributing to the contamination of hospital water distribution systems by legionellae. *J Infect Dis* 1992; 165:565–569.
 88. Kool JL, Bergmire-Sweat D, Butler JC, et al. Hospital characteristics associated with colonization of water systems by *Legionella* and risk of nosocomial Legionnaires' disease: a cohort study of 15 hospitals. *Infect Control Hosp Epidemiol* 1999;20:798–805.
 89. Fields BS, Benson RF, Besser RE. Legionella and Legionnaires' disease: 25 years of investigation. *Clin Microbiol Rev* 2002;15: 506–526.
 90. Graman PS, Quinlan GA, Rank JA. Nosocomial legionellosis traced to a contaminated ice machine. *Infect Control Hosp Epidemiol* 1997;18:637–640.
 91. Venezia RA, Agresta MD, Hanley EM, Urquhart K, Schoonmaker D. Nosocomial legionellosis associated with aspiration of nasogastric feedings diluted in tap water. *Infect Control Hosp Epidemiol* 1994;15:529–533.
 92. Darelid J, Bengtsson L, Gastrin B, et al. An outbreak of Legionnaires' disease in a Swedish hospital. *Scand J Infect Dis* 1994;26: 417–425.
 93. Nechwatal R, Ehret W, Klatte OJ, Zeissler HJ, Prull A, Lutz H. Nosocomial outbreak of legionellosis in a rehabilitation center. Demonstration of potable water as a source. *Infection* 1993;21:235–240.
 94. Levin AS, Caiaffa Filho HH, Sinto SI, Sabbaga E, Barone AA, Mendes CM. An outbreak of nosocomial Legionnaires' disease in a renal transplant unit in Sao Paulo, Brazil. *Legionellosis Study Team J Hosp Infect* 1991;18:243–248.
 95. Kool JL, Fiore AE, Kioski CM, et al. More than 10 years of unrecognized nosocomial transmission of Legionnaires' disease among transplant patients. *Infect Control Hosp Epidemiol* 1998;19:898–904.

96. Hanrahan JP, Morse DL, Scharf VB, et al. A community hospital outbreak of legionellosis. Transmission by potable hot water. *Am J Epidemiol* 1987;125:639–649.
97. Stout J, Yu VL, Vickers RM, Shonnard J. Potable water supply as the hospital reservoir for Pittsburgh pneumonia agent. *Lancet* 1982; 1:471–472.
98. Helms CM, Massanari RM, Zeitler R, et al. Legionnaires' disease associated with a hospital water system: a cluster of 24 nosocomial cases. *Ann Intern Med* 1983;99:172–178.
99. Muscarella LF. Contribution of tap water and environmental surfaces to nosocomial transmission of antibiotic-resistant *Pseudomonas aeruginosa*. *Infect Control Hosp Epidemiol* 2004;25:342–345.
100. Schelenz S, French G. An outbreak of multidrug-resistant *Pseudomonas aeruginosa* infection associated with contamination of bronchoscopes and an endoscope washer-disinfector. *J Hosp Infect* 2000; 46(1):23–30.
101. Sorin M, Segal-Maurer S, Mariano N, Urban C, Combest A, Rahal JJ. Nosocomial transmission of imipenem-resistant *Pseudomonas aeruginosa* following bronchoscopy associated with improper connection to the Steris System 1 processor. *Infect Control Hosp Epidemiol* 2001;22(7):409–413.
102. Srinivasan A, Wolfenden LL, Song X, Mackie K, Hartsell TL, Jones HD, et al. An outbreak of *Pseudomonas aeruginosa* infections associated with flexible bronchoscopes. *N Engl J Med* 2003; 348(3):221–227.
103. Wheeler PW, Lancaster D, Kaiser AB. Bronchopulmonary cross-colonization and infection related to mycobacterial contamination of suction valves of bronchoscopes. *J Infect Dis* 1989;159(5):954–958.
104. Michele TM, Cronin WA, Graham NM, Dwyer DM, Pope DS, Harrington S, et al. Transmission of *Mycobacterium tuberculosis* by a fiberoptic bronchoscope. Identification by DNA fingerprinting. *JAMA* 1997;278(13):1093–1095.
105. Fraser VJ, Jones M, Murray PR, Medoff G, Zhang Y, Wallace RJ Jr. Contamination of flexible fiberoptic bronchoscopes with *Mycobacterium chelonae* linked to an automated bronchoscope disinfection machine. *Am Rev Respir Dis* 1992;145(4 Pt 1):853–855.
106. Agerton T, Valway S, Gore B, Pozsik C, Plikaytis B, Woodley C, Onorato I. Transmission of a highly drug-resistant strain (strain W1) of *Mycobacterium tuberculosis*. Community outbreak and nosocomial transmission via a contaminated bronchoscope. *JAMA* 1997;278(13):1073–1077.
107. Weber DJ, Rutala WA. Lessons from outbreaks associated with bronchoscopy. *Infect Control Hosp Epidemiol* 2001;22(7):403–408.
108. Walter VA, DiMarino AJ Jr. American Society for Gastrointestinal Endoscopy-Society of Gastroenterology Nurses and Associates Endoscope Reprocessing Guidelines. *Gastrointest Endosc Clin N Am* 2000;10(2):265–273.
109. Moolenaar RL, Crutcher JM, San Joaquin VH, et al. A prolonged outbreak of *Pseudomonas aeruginosa* in a neonatal intensive care unit: did staff fingernails play a role in disease transmission? *Infect Control Hosp Epidemiol* 2000;21:80–85.
110. Gupta A, Della-Latta P, Todd B, et al. Outbreak of extended-spectrum beta-lactamase-producing *Klebsiella pneumoniae* in a neonatal intensive care unit linked to artificial nails. *Infect Control Hosp Epidemiol* 2004;25:210–215.
111. Shamseldin el Shafie S, Smith W, Donnelly G. An outbreak of gentamicin-resistant *Klebsiella pneumoniae* in a neonatal ward. *Cent Eur J Public Health* 1995;3:129–131.
112. Zawacki A, O'Rourke E, Potter-Bynoe G, Macone A, Harbarth S, Goldmann D. An outbreak of *Pseudomonas aeruginosa* pneumonia and bloodstream infection associated with intermittent otitis externa in a healthcare worker. *Infect Control Hosp Epidemiol* 2004;25: 1083–1089.
113. Gras-Le Guen C, Lepelletier D, Debillon T, Gournay V, Espaze E, Roze JC. Contamination of a milk bank pasteuriser causing a *Pseudomonas aeruginosa* outbreak in a neonatal intensive care unit. *Arch Dis Child Fetal Neonatal Ed* 2003;88:F434–F435.
114. Garland SM, Mackay S, Tabrizi S, Jacobs S. *Pseudomonas aeruginosa* outbreak associated with a contaminated blood-gas analyser in a neonatal intensive care unit. *J Hosp Infect* 1996;33:145–151.
115. Matrician L, Ange G, Burns S, et al. Outbreak of nosocomial *Burkholderia cepacia* infection and colonization associated with intrinsically contaminated mouthwash. *Infect Control Hosp Epidemiol* 2000;21:739–741.
116. File TM, Jr., Tan JS, Thomson RB, Jr., Stephens C, Thompson P. An outbreak of *Pseudomonas aeruginosa* ventilator-associated respiratory infections due to contaminated food coloring dye—further evidence of the significance of gastric colonization preceding nosocomial pneumonia. *Infect Control Hosp Epidemiol* 1995;16:417–448.
117. Gravel D, Sample ML, Ramotar K, Toye B, Oxley C, Garber G. Outbreak of *Burkholderia cepacia* in the adult intensive care unit traced to contaminated indigo-carmin dye. *Infect Control Hosp Epidemiol* 2002;23:103–106.
118. World Health Organization. Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. Available at http://www.who.int/csr/sars/country/table2003_09_23/en. Accessed March 31, 2005.
119. Peiris JS, Yuen KY, Osterhaus AD, Stohr K. The severe acute respiratory syndrome. *N Engl J Med* 2003;349(25):2431–2441.
120. Lipsitch M, Cohen T, Cooper B, Robins JM, Ma S, James L, et al. Transmission dynamics and control of severe acute respiratory syndrome. *Science* 2003;300(5627):1966–1970.
121. Drinka PJ, Gravenstein S, Krause P, Langer EH, Barthels L, Dissing M, et al. Non-influenza respiratory viruses may overlap and obscure influenza activity. *J Am Geriatr Soc* 1999;47(9):1087–1093.
122. Drinka PJ, Gravenstein S, Krause P, Schilling M, Miller BA, Shult P. Outbreaks of influenza A and B in a highly immunized nursing home population. *J Fam Pract* 1997;45(6):509–514.
123. Drinka PJ, Gravenstein S, Schilling M, Krause P, Miller BA, Shult P. Duration of antiviral prophylaxis during nursing home outbreaks of influenza A: a comparison of 2 protocols. *Arch Intern Med* 1998;158(19):2155–2159.
124. Drinka PJ, Krause P, Schilling M, Miller BA, Shult P, Gravenstein S. Report of an outbreak: nursing home architecture and influenza-A attack rates. *J Am Geriatr Soc* 1996;44(8):910–913.
125. Gravenstein S, Ambrozaitis A, Schilling M, Radzisauskiene D, Krause P, Drinka P, et al. Surveillance for respiratory illness in long-term care settings: detection of illness using a prospective research technique. *J Am Med Dir Assoc* 2000;1(3):122–128.
126. Schilling M, Gravenstein S, Drinka P, Cox N, Krause P, Povinelli L, Shult P. Emergence and transmission of amantadine-resistant influenza A in a nursing home. *J Am Geriatr Soc* 2004;52(12): 2069–2073.
127. Schilling M, Povinelli L, Krause P, Gravenstein M, Ambrozaitis A, Jones HH, et al. Efficacy of zanamivir for chemo-prophylaxis of nursing home influenza outbreaks. *Vaccine* 1998;16(18):1771–1774.
128. Centers for Disease Control and Prevention (CDC). Tuberculosis outbreak in a community hospital—District of Columbia, 2002. *MMWR Morb Mortal Wkly Rep* 2004;19(10):214–216.
129. Young LS, Perdreaux-Remington F, Winston LG. Clinical, epidemiological and molecular evaluation of a clonal outbreak of methicillin-resistant *Staphylococcus aureus* infection. *Clin Infect Dis* 2004;38:1075–1083.
130. Seto WH, Tsang D, Yung RW, et al. Expert SARS. Group of hospital authority. Effectiveness of precautions against droplets and

- contact in prevention of nosocomial transmission of severe acute respiratory syndrome. *Lancet* 2003;361:1519–1520.
131. Lee N, Hui D, Wu A, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. *N Engl J Med* 2003;348:1986–1994.
 132. Organization Wh. World Health Organization Consensus Document on the epidemiology of severe acute respiratory syndrome (SARS). Available at www.int/csr/sars/en/WHOconsensus.pdf 2004.
 133. Salgado CD, Farr BM, Hall KK, Hayden FG. Influenza in the acute hospital setting. *Lancet Infect Dis* 2002;1:38–45.
 134. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. *Clin Infect Dis* 2002;34:909–917.
 135. Pegues DA, Lasker BA, McNeil MM, Hamm PM, Lundal JL, Kubak BM. Cluster of cases of invasive aspergillosis in a transplant intensive care unit: evidence of person-to-person airborne transmission. *Clin Infect Dis* 2002;34:412–416.
 136. Sherertz RJ, Belani A, Kramer BS, et al. Impact of air filtration on nosocomial aspergillus infections. Unique risk of bone marrow transplant recipients. *Am J Med* 1987;83:709–718.
 137. Oren I, Haddad N, Finkelstein R, Rowe JM. Invasive pulmonary aspergillosis in neutropenic patients during hospital construction: before and after chemoprophylaxis and institution of HEPA filters. *Am J Hematol* 2001;66:257–262.
 138. Krasinski K, Holzman RS, Hanna B, Greco MA, Graff M, Bhogal M. Nosocomial fungal infection during hospital renovation. *Infection Control* 1985;6:278–282.
 139. Weems JJ, Jr., Davis BJ, Tablan OC, Kaufman L, Martone WJ. Construction activity: an independent risk factor for invasive aspergillosis and zygomycosis in patients with hematologic malignancy. *Infection Control* 1987;8:71–75.
 140. Flynn PM, Williams BG, Hetherington SV, Williams BF, Giannini MA, Pearson TA. *Aspergillus terreus* during hospital renovation. *Infect Control Hosp Epidemiol* 1993;14:363–365.
 141. Buffington J, Reporter R, Lasker BA, et al. Investigation of an epidemic of invasive aspergillosis: utility of molecular typing with the use of random amplified polymorphic DNA probes. *Pediatr Infect Dis J* 1994;13:386–393.
 142. Iwen PC, Davis JC, Reed EC, Winfield BA, Hinrichs SH. Airborne fungal spore monitoring in a protective environment during hospital construction, and correlation with an outbreak of invasive aspergillosis. *Infect Control Hosp Epidemiol* 1994;15:303–306.
 143. Anderson K, Morris G, Kennedy H, et al. Aspergillosis in immunocompromised paediatric patients: associations with building hygiene, design, and indoor air. *Thorax* 1996;51:256–261.
 144. Loo VG, Bertrand C, Dixon C, et al. Control of construction-associated nosocomial aspergillosis in an antiquated hematology unit. *Infect Control Hosp Epidemiol* 1996;17:360–364.
 145. Sessa A, Meroni M, Battini G, et al. Nosocomial outbreak of *Aspergillus fumigatus* infection among patients in a renal unit? *Neph Dial Transplantation* 1996;11:1322–1324.
 146. Tabbara KF, al Jabarti AL. Hospital construction-associated outbreak of ocular aspergillosis after cataract surgery. *Ophthalmology* 1998;105:522–526.
 147. Lai KK. A cluster of invasive aspergillosis in a bone marrow transplant unit related to construction and the utility of air sampling. *Am J Infection Control* 2001;29:333–337.
 148. Panackal AA, Dahlman A, Keil KT, et al. Outbreak of invasive aspergillosis among renal transplant recipients. *Transplantation* 2003;75:1050–1053.
 149. Meduri GU, Estes RJ. The pathogenesis of ventilator-associated pneumonia: II. The lower respiratory tract. *Intensive Care Med* 1995;21(5):452–461.
 150. Scannapieco FA, Stewart EM, Mylotte JM. Colonization of dental plaque by respiratory pathogens in medical intensive care patients. *Crit Care Med* 1992;20(6):740–745.
 151. Bonten MJ, Gaillard CA, van Tiel FH, Smeets HG, van der Geest S, Stobberingh EE. The stomach is not a source for colonization of the upper respiratory tract and pneumonia in ICU patients. *Chest* 1994;105(3):878–884.
 152. Niederman MS, Mantovani R, Schoch P, Papas J, Fein AM. Patterns and routes of tracheobronchial colonization in mechanically ventilated patients. The role of nutritional status in colonization of the lower airway by *Pseudomonas* species. *Chest* 1989;95(1):155–161.
 153. Cardenosa Cendrero JA, Sole-Violan J, Bordes Benitez A, Noguera Catalan J, Arroyo Fernandez J, Saavedra Santana P, Rodriguez de Castro F. Role of different routes of tracheal colonization in the development of pneumonia in patients receiving mechanical ventilation. *Chest* 1999;116(2):462–470.
 154. Niederman MS. Gram-negative colonization of the respiratory tract: pathogenesis and clinical consequences. *Semin Respir Infect* 1990;5(3):173–184.
 155. DeRiso AJ, 2nd, Ladowski JS, Dillon TA, Justice JW, Peterson AC. Chlorhexidine gluconate 0.12% oral rinse reduces the incidence of total nosocomial respiratory infection and nonprophylactic systemic antibiotic use in patients undergoing heart surgery. *Chest* 1996;109(6):1556–1561.
 156. Houston S, Hougland P, Anderson JJ, LaRocco M, Kennedy V, Gentry LO. Effectiveness of 0.12% chlorhexidine gluconate oral rinse in reducing prevalence of nosocomial pneumonia in patients undergoing heart surgery. *Am J Crit Care* 2002;11(6):567–570.
 157. Fourrier F, Cau-Pottier E, Boutigny H, Roussel-Delvallez M, Jourdain M, Chopin C. Effects of dental plaque antiseptic decontamination on bacterial colonization and nosocomial infections in critically ill patients. *Intensive Care Med* 2000;26(9):1239–1247.
 158. Grap MJ, Munro CL, Elswick RK Jr., Sessler CN, Ward KR. Duration of action of a single, early oral application of chlorhexidine on oral microbial flora in mechanically ventilated patients: a pilot study. *Heart Lung* 2004;33(2):83–91.
 159. du Moulin GC, Paterson DG, Hedley-Whyte J, Lisbon A. Aspiration of gastric bacteria in antacid-treated patients: a frequent cause of postoperative colonisation of the airway. *Lancet* 1982;1(8266):242–245.
 160. Daschner F, Kappstein I, Engels I, Reuschenbach K, Pfisterer J, Krieg N, Vogel W. Stress ulcer prophylaxis and ventilation pneumonia: prevention by antibacterial cytoprotective agents? *Infect Control Hosp Epidemiol* 1988;9(2):59–65.
 161. Giannella RA, Broitman SA, Zamcheck N. Influence of gastric acidity on bacterial and parasitic enteric infections. A perspective. *Ann Intern Med* 1973;78(2):271–276.
 162. Donowitz LG, Page MC, Mileur BL, Guenther SH. Alteration of normal gastric flora in critical care patients receiving antacid and cimetidine therapy. *Infect Control* 1986;7(1):23–26.
 163. Heyland D, Mandell LA. Gastric colonization by gram-negative bacilli and nosocomial pneumonia in the intensive care unit patient. Evidence for causation. *Chest* 1992;101(1):187–193.
 164. Torres A, el-Ebiary M, Gonzalez J, Ferrer M, Puig de la Bellacasa J, Gene A, et al. Gastric and pharyngeal flora in nosocomial pneumonia acquired during mechanical ventilation. *Am Rev Respir Dis* 1993;148(2):352–357.
 165. Inglis TJ, Sherratt MJ, Sproat LJ, Gibson JS, Hawkey PM. Gastrointestinal dysfunction and bacterial colonisation of the ventilated lung. *Lancet* 1993;341(8850):911–913.
 166. Torres A, Serra-Batlles J, Ros E, Piera C, Puig de la Bellacasa J, Cobos A, Lomena F, Rodriguez-Roisin R. Pulmonary aspiration of

- gastric contents in patients receiving mechanical ventilation: the effect of body position. *Ann Intern Med* 1992;116(7):540–543.
167. Ibanez J, Penafiel A, Marse P, Jorda R, Raurich JM, Mata F. Incidence of gastroesophageal reflux and aspiration in mechanically ventilated patients using small-bore nasogastric tubes. *JPEN J Parenter Enteral Nutr* 2000;24(2):103–106.
 168. Garroute-Orgeas M, Chevret S, Arlet G, Marie O, Rouveau M, Popoff N, Schlemmer B. Oropharyngeal or gastric colonization and nosocomial pneumonia in adult intensive care unit patients. A prospective study based on genomic DNA analysis. *Am J Respir Crit Care Med* 1997;156(5):1647–1655.
 169. Bonten MJ, Gaillard CA, van der Geest S, van Tiel FH, Beysens AJ, Smeets HG, Stobberingh EE. The role of intragastric acidity and stress ulcer prophylaxis on colonization and infection in mechanically ventilated ICU patients. A stratified, randomized, double-blind study of sucralfate versus antacids. *Am J Respir Crit Care Med* 1995;152(6 Pt 1):1825–1834.
 170. Bonten MJ, Bergmans DC, Ambergen AW, de Leeuw PW, van der Geest S, Stobberingh EE, Gaillard CA. Risk factors for pneumonia, and colonization of respiratory tract and stomach in mechanically ventilated ICU patients. *Am J Respir Crit Care Med* 1996;154(5):1339–1346.
 171. Geller DE, Pitlick WH, Nardella PA, Tracewell WG, and Ramsey BW. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. *Chest* 2002;122(1):219–226.
 172. Hamer DH. Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant *Pseudomonas aeruginosa* with aerosolized colistin. *Amer J Resp Crit Care Med* 2000;162(1):328–330.
 173. Sobieszczyk ME, Furuya EY, Hay CM, Pancholi P, Della-Latta P, Hammer SM, Kubin CJ. Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections. *Journal of Antimicrobial Chemotherapy* 2004;54(2):566–569.
 174. Brown RB, Kruse JA, Counts GW, Russell JA, Christou NV, and Sands ML. Double-blind study of endotracheal tobramycin in the treatment of gram-negative bacterial pneumonia. The Endotracheal Tobramycin Study Group. *Antimicrob Agents Chemother* 1990;34(2):269–272.
 175. Klick JM, du Moulin GC, Hedley-Whyte J, Teres D, Bushnell LS, Feingold DS. Prevention of gram-negative bacillary pneumonia using polymyxin aerosol as prophylaxis. II. Effect on the incidence of pneumonia in seriously ill patients. *J Clin Invest* 1975;55(3):514–519.
 176. Denton M, Kerr K, Mooney L, Keer V, Rajgopal A, Brownlee K, Arundel P, Conway S. Transmission of colistin-resistant *Pseudomonas aeruginosa* between patients attending a pediatric cystic fibrosis center. *Pediatr Pulmonol.* 2002;34(4):257–261.
 177. Krueger WA, Unertl KE. Selective decontamination of the digestive tract. *Curr Opin Crit Care* 2002;8(2):139–144.
 178. de Jonge E, Schultz MJ, Spanjaard L, Bossuyt PM, Vroom MB, Dankert J, Kesecioglu J. Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial. *Lancet* 2003;362(9389):1011–1016.
 179. Sanchez Garcia M, Cambrero Galache JA, Lopez Diaz J, Cerda Cerda E, Rubio Blasco J, Gomez Aguinaga MA, et al. Effectiveness and cost of selective decontamination of the digestive tract in critically ill intubated patients. A randomized, double-blind, placebo-controlled, multicenter trial. *Am J Respir Crit Care Med* 1998;158(3):908–916.
 180. Winter R, Humphreys H, Pick A, MacGowan AP, Willatts SM, Speller DC. A controlled trial of selective decontamination of the digestive tract in intensive care and its effect on nosocomial infection. *J Antimicrob Chemother* 1992;30(1):73–87.
 181. Meta-analysis of randomised controlled trials of selective decontamination of the digestive tract. Selective Decontamination of the Digestive Tract Trialists' Collaborative Group. *BMJ* 1993;307(6903):525–532.
 182. Safdar N, Said A, Lucey MR. The role of selective digestive decontamination for reducing infection in patients undergoing liver transplantation: a systematic review and meta-analysis. *Liver Transpl* 2004;10(7):817–827.
 183. Nathens AB, Marshall JC. Selective decontamination of the digestive tract in surgical patients: a systematic review of the evidence. *Arch Surg* 1999;134(2):170–176.
 184. Kollef MH. The role of selective digestive tract decontamination on mortality and respiratory tract infections. A meta-analysis. *Chest* 1994;105(4):1101–1108.
 185. Heyland DK, Cook DJ, Jaeschke R, Griffith L, Lee HN, Guyatt GH. Selective decontamination of the digestive tract. An overview. *Chest* 1994;105(4):1221–1229.
 186. Bonten MJ, Grundmann H. Selective digestive decontamination and antibiotic resistance: a balancing act. *Crit Care Med* 2003;31(8):2239–2240.
 187. Ebner W, Kropec-Hubner A, Daschner FD. Bacterial resistance and overgrowth due to selective decontamination of the digestive tract. *Eur J Clin Microbiol Infect Dis* 2000;19(4):243–247.
 188. Drakulovic MB, Torres A, Bauer TT, Nicolas JM, Nogue S, Ferrer M. Supine body position as a risk factor for nosocomial pneumonia in mechanically ventilated patients: a randomised trial. *Lancet* 1999;354(9193):1851–1858.
 189. Smulders K, van der Hoeven H, Weers-Pothoff I, Vandembroucke-Grauls C. A randomized clinical trial of intermittent subglottic secretion drainage in patients receiving mechanical ventilation. *Chest* 2002;121(3):858–862.
 190. Mahul P, Auboyer C, Jospe R, Ros A, Guerin C, el Khouri Z, et al. Prevention of nosocomial pneumonia in intubated patients: respective role of mechanical subglottic secretions drainage and stress ulcer prophylaxis. *Intensive Care Med* 1992;18(1):20–25.
 191. Kollef MH, Skubas NJ, Sundt TM. A randomized clinical trial of continuous aspiration of subglottic secretions in cardiac surgery patients. *Chest* 1999;116(5):1339–1346.
 192. Valles J, Artigas A, Rello J, Bonsoms N, Fontanals D, Blanch L, et al. Continuous aspiration of subglottic secretions in preventing ventilator-associated pneumonia. *Ann Intern Med* 1995;122(3):179–186.
 193. Koerner RJ. Contribution of endotracheal tubes to the pathogenesis of ventilator-associated pneumonia. *J Hosp Infect* 1997;35(2):83–89.
 194. Adair CG, Gorman SP, Feron BM, Byers LM, Jones DS, Goldsmith CE, et al. Implications of endotracheal tube biofilm for ventilator-associated pneumonia. *Intensive Care Med* 1999;25(10):1072–1076.
 195. Feldman C, Kassel M, Cantrell J, Kaka S, Morar R, Goolam Mahomed A, Philips JJ. The presence and sequence of endotracheal tube colonization in patients undergoing mechanical ventilation. *Eur Respir J* 1999;13(3):546–551.
 196. Pacheco-Fowler V, Gaonkar T, Wyer PC, Modak S. Antiseptic impregnated endotracheal tubes for the prevention of bacterial colonization. *J Hosp Infect* 2004;57(2):170–174.
 197. Olson ME, Harmon BG, Kollef MH. Silver-coated endotracheal tubes associated with reduced bacterial burden in the lungs of mechanically ventilated dogs. *Chest* 2002;121(3):863–870.
 198. Holzapfel L, Chastang C, Demingon G, Bohe J, Piralla B, Coupry A. A randomized study assessing the systematic search for maxillary sinusitis in nasotracheally mechanically ventilated patients. Influence of nosocomial maxillary sinusitis on the occurrence of ventilator-associated pneumonia. *Am J Respir Crit Care Med* 1999;159(3):695–701.

199. Rouby JJ, Laurent P, Gosnach M, Cambau E, Lamas G, Zouaoui A, et al. Risk factors and clinical relevance of nosocomial maxillary sinusitis in the critically ill. *Am J Respir Crit Care Med* 1994; 150(3):776–783.
200. Souweine B, Mom T, Traore O, Aublet-Cuvelier B, Bret L, Sirot J, et al. Ventilator-associated sinusitis: microbiological results of sinus aspirates in patients on antibiotics. *Anesthesiology* 2000;93(5): 1255–1260.
201. Kollef MH, Shapiro SD, Fraser VJ, Silver P, Murphy DM, Trovillion E, et al. Mechanical ventilation with or without 7-day circuit changes. A randomized controlled trial. *Ann Intern Med* 1995; 123(3):168–174.
202. Goularte TA, Manning M, Craven DE. Bacterial colonization in humidifying cascade reservoirs after 24 and 48 hours of continuous mechanical ventilation. *Infect Control* 1987;8(5):200–203.
203. Deppe SA, Kelly JW, Thoi LL, Chudy JH, Longfield RN, Ducey JP, et al. Incidence of colonization, nosocomial pneumonia, and mortality in critically ill patients using a Trach Care closed-suction system versus an open-suction system: prospective, randomized study. *Crit Care Med* 1990;18(12):1389–1393.

Discussion

MacIntyre: What is your take on Gerry Smaldone’s idea that maybe you should aerosolize these antibiotics into the airway as a preventive measure to prevent colonization?

Maki: I will talk about that this afternoon.

Solomkin: Do you think that solid-organ-transplant patients should be managed the same way as other high-risk ICU patients?

Maki: I’ll tell you about that this afternoon, but, in a nutshell, the answer to your question, I think, is yes, because they’re much more vulnerable to colonization and infection by resistant organisms. That is the greatest challenge of these patients. If you do liver transplantation, you’re going to have a lot more VRE [vancomycin-resistant enterococcus], a lot more beta-lactamase-producing Gram-negative rods, and more MRSA [methicillin-resistant *Staphylococcus aureus*] in your unit or in your hospital. I think you have to accommodate this in your preventive strategies.

Solomkin: Do you think those differences are because of physiologic changes in the host?

Maki: No. Do you know what the greatest risk factor is for picking up MRSA in the hospital, or VRE? It’s how long you’re hospitalized. Length of stay is such a powerful risk factor that when we do multivariable mod-

eling with large databases, if we leave it in the model, it’s hard to find other risk factors. The longer you are in the hospital, the more likely you are to pick up a resistant organism.

We’re now about 600 patients into a prospective study that’s been going on for 2 years, in which we are culturing for 5 resistant organisms when a patient enters the hospital and every 5 days thereafter until the patient goes home, and length of stay is a huge risk factor. Liver transplant patients have a length of stay that is 3 times the average of other patients. They’ve often already spent time in other hospitals and other ICUs, getting their liver disease and gastrointestinal bleeding treated, so they often arrive colonized by resistant organisms, but they acquire even more nosocomial organisms in your hospital following the transplant.

Kollef: I want to echo that. I participated in a study, with Linda Mundy, looking at our ICU gowning practices in regard to VRE colonization, and we basically found that in the multivariable analysis there was a compound effect: that the gowning had its greatest effect in preventing VRE colonization with patients who spent more than 10 days in the ICU.^{1,2} The problem, I think, from an infection-control perspective is that people are looking for that quick fix in terms of where it’s going to have an impact and not recognizing that it may be a very specific population in the ICU—often the more compromised patients who do spend longer time in the ICU.

REFERENCES

1. Puzniak LA, Gillespie KN, Leet T, Kollef M, Mundy LM. A cost-benefit analysis of gown use in controlling vancomycin-resistant Enterococcus transmission: is it worth the price? *Infect Control Hosp Epidemiol* 2004;25(5):418–424.
2. Puzniak LA, Leet T, Mayfield J, Kollef M, Mundy LM. To gown or not to gown: the effect on acquisition of vancomycin-resistant enterococci. *Clin Infect Dis* 2002;35(1): 18–25.

Maki: I think it’s feasible to target high-risk patients for special interventions.

Kollef: In regard to oral decontamination with either antimicrobial agents or antiseptic agents, when you look at the chlorhexidine data, there are some issues with those studies.^{1,2} They have tended to be small, they haven’t been blinded, and one thing they didn’t look at was VAP-free survival, and they really weren’t powered to look at VAP in the survivors. Even the studies that have been done, including Mark Bonten’s study³—and I’ve talked to him about this a number of times—they’re not truly randomized double-blinded studies in that regard, and I’m a little worried, because there is a trend going on now in terms of just using chlorhexidine and assuming that it may fix many of the problems for us. Part of the reason I raise this concern is that when we recently finished this oral decontamination study using this antimicrobial peptide, we found that the signal was very small. The only place we found a signal was in the trauma population.

REFERENCES

1. Houston S, Hougland P, Anderson JJ, La-Rocco M, Kennedy V, Gentry LO. Effectiveness of 0.12% chlorhexidine gluconate oral rinse in reducing prevalence of nosocomial pneumonia in patients undergoing heart surgery. *Am J Crit Care* 2002;11(6):567-570.
2. DeRiso AJ 2nd, Ladowski JS, Dillon TA, Justice JW, Peterson AC. Chlorhexidine gluconate 0.12% oral rinse reduces the incidence of total nosocomial respiratory infection and nonprophylactic systemic antibiotic use in patients undergoing heart surgery. *Chest* 1996;109(6):1556-1561.
3. Bergmans DC, Bonten MJ, Gaillard CA, Paling JC, van der Geest S, van Tiel FH, et al. Prevention of ventilator-associated pneumonia by oral decontamination: a prospective, randomized, double-blind, placebo-controlled study. *Am J Respir Crit Care Med* 2001;164(3):382-388.

Maki: I think you are absolutely right. I don't think the use of chlorhexidine topically in the oropharynx is a done deal. It's a work in progress. It's very interesting and promising. What's attractive about it is that it's unlikely to select for resistance, and it's simple. It's going to be relatively nontoxic and safe; it shouldn't be terribly expensive. But it's not been studied sufficiently so that we can conclude it's a Category 1A recommendation. It would benefit greatly from a multicenter trial, ideally, a blinded trial.

Kollef: Do you think that maybe we're going to be looking at combinations of preventive approaches? Maybe using something like chlorhexidine, maybe having something that prevents a biofilm in place? This afternoon I think you are going to be overwhelmed, because the reality of life is that if we don't have a multifaceted approach to prevention, we're in big trouble. We have to have multifaceted approaches.

Ventilator-associated pneumonia, in my opinion, is the most formidable of all the infections we deal with. It's relatively simple to prevent line sepsis. It's relatively simple to reduce the risk of surgical-site infection with specific strategies. The urinary tract and

respiratory tract are still *very* formidable problems, because you have a tube passing through a very heavily colonized surface, and there is the possibility of mass transport. I mean if a bolus of 10^6 organisms goes zipping down the tube, I don't think anything you do on the surface or in the urinary tract is going to do anything about that, and you need to have a multifaceted approach to deal with that, as well as stuff seeping along the side, where biofilms may play a role.

Niederman: I think you stated that most pathogenesis begins with oropharyngeal colonization, and I think that that isn't necessarily true—at least it hasn't been in some of the things that I've been involved with. I think you have to make a distinction in whether it's an early pneumonia or late pneumonia and specifically what the pathogen is. I think an important pathogen where that may not always be true is *Pseudomonas*, about which a number of studies¹⁻⁴ show that you can get primary tracheal colonization without preceding oropharyngeal colonization.

REFERENCES

1. Niederman MS, Mantovani R, Schoch P, Papas J, Fein AM. Patterns and routes of tracheobronchial colonization in mechanically ventilated patients. The role of nutritional status in colonization of the lower airway by *Pseudomonas* species. *Chest* 1989;95(1):155-161.
2. Niederman MS, Ferranti RD, Zeigler A, Merrill WW, Reynolds HY. Respiratory infection complicating long-term tracheostomy. The implication of persistent gram-negative tracheobronchial colonization. *Chest* 1984;85(1):39-44.
3. Cardenosa Cendrero JA, Sole-Violan J, Bordes Benitez A, Noguera Catalan J, Arroyo Fernandez J, et al. Role of different routes of tracheal colonization in the development of pneumonia in patients receiving mechanical ventilation. *Chest* 1999;116(2):462-470.
4. Berthelot P, Grattard F, Mahul P, Pain P, Jospe R, Venet C, et al. Prospective study of nosocomial colonization and infection due to *Pseudomonas aeruginosa* in mechanically ventilated patients. *Intensive Care Med* 2001;27(3):503-512.

Maki: I'm convinced that most of those probably come from condensate.

Niederman: Whether it's condensate, the environment, or the hands of the staff, consistently the subglottic secretion drainage studies show that they're not very effective at both late pneumonia and *Pseudomonas* pneumonia.

Maki: Let me comment on a shortcoming of a lot of the studies of looking at the linkage between oropharyngeal colonization and VAP. First, if you really want to be able to detect low-level colonization by target pathogens such as MRSA, you should probably culture daily. Second, you should use selective media. If you don't use selective media, it's hard to detect small populations that may be there.

Niederman: But I think that, at least conceptually, even if the methodology of those serial culture studies isn't perfect, the subglottic secretion-drainage tubes don't work great for late-onset pneumonia or *Pseudomonas* pneumonia, and that may be the explanation. With regard to biofilm, as I think you were describing it and as many people have conceptualized it, this is material that is produced primarily by the bacteria, but the other important component in this system, which I don't think is addressed by any of these prophylactic strategies, is the mucus in the airway. I think that may be one of the reasons why the antibacterial approach may not work: because even if you have a completely sterile biofilm, mucus will bind to the endotracheal tube very effectively, and bacteria will stick to the mucus, probably better than they will stick to anything else. That's why mucus is there. Mucus is effective at removing bacteria because it binds them so well. But if you happen to have stagnation and sticking of that mucus to the endotracheal tube, then it's a bridge to colonization and infection. So I do think that unless we can combine an antibacterial approach with some-

THE PATHOGENESIS OF VENTILATOR-ASSOCIATED PNEUMONIA

thing that would prevent mucus from binding to the tube, it's probably not going to be effective.

Maki: I think your point's well taken.

Hess: A question of semantics. If the problem is the endotracheal tube, why do we keep calling it *ventilator-associated pneumonia*?

Maki: That's a very legitimate point.

I think a patient who has just had a tracheostomy but is not necessarily on a ventilator, has many of the same vulnerabilities. It would probably be more appropriate to call it *endotracheal-tube-associated pneumonia*.



Pneumonia ward, U.S. Army
Camp Hospital, Humes, France, 1918
Courtesy National Library of Medicine